West Pharmaceutical Services, Inc. Profile Avatar - Palmy Investing

West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprie…
Medical - Instruments & Supplies
US, Exton [HQ]

FA

Fundamental Analysis · Most Recent Quarter

It is important to understand the FA Algorithm and the criterias before valuing it as a top-tier resource.

Read Rationale
Framework:
Valuation 14% Weak
Profitability n.A. n.A.
Fin. Growth 0% Bad
Leverage & Liquidity 17% Weak
Per Share Metrics 0% Bad
Fin. Health n.A. n.A.
Fundamentals

Valuation

Metric Q4 Q1 Δ in %
EV/EBITDA 52.34 181.86 119.38
Graham Fair Price -10.79 35.88 40.22
PEG -29.12 -4.17 -3.23
Price/Book 19.87 10.86 9.06
Price/Cash Flow 426.96 1054.41 200.09
Prices/Earnings 32.53 63.10 47.61
Price/Sales 17.40 41.85 35.64
Price/FCF 426.96 1054.41 200.09
Naive Interpretation member
01 - Valuation · Weak
Fundamentals

Profitability

Metric Q4 Q1 Δ in %
Gross Profit Margin -12.90 0.33 0.38
Operating Margin -19.66 0.18 0.22
ROA -10.53 0.03 0.04
ROE 0.05 0.04 -9.55
ROIC 0.04 0.04 -10.67
Naive Interpretation member
02 - Profitability · Not Interpreted
Fundamentals

Financial Growth

Metric Q4 Q1 Δ in %
Debt QOQ < 0.005 < 0.005 8.31
Dividends QOQ 0.06 < 0.005 -97.75
EBIT QOQ -0.09 -0.24 -156.00
EPS QOQ -0.15 -0.15 -2.64
FCF QOQ -0.03 -0.79 -2614.73
Revenue QOQ -0.02 -0.05 -142.66
Naive Interpretation member
03 - Financial Growth · Bad
Fundamentals

Leverage & Liquidity

Metric Q4 Q1 Δ in %
Assets Turnover n.A. n.A. n.A.
Days Inventory Outstanding (DIO) 86.21 83.17 -3.53
Days Sales Outstanding (DSO) 62.95 67.82 7.73
Inventory Turnover 1.04 1.08 3.66
Debt/Capitalization 0.10 0.10 5.96
Quick Ratio 2.03 1.74 -14.60
Naive Interpretation member
04 - Leverage & Liquidity · Weak
Fundamentals

Per Share Metrics

Metric Q4 Q1 Δ in %
Book Value 38.88 36.47 -6.20
Cash 11.52 8.19 -28.95
Capex -1.47 -1.23 15.97
Free Cash Flow 1.76 0.38 -78.66
Revenue 9.88 9.46 -4.22
Naive Interpretation member
05 - Per Share Metrics · Bad
Fundamentals

Financial Health

Metric Q4 Q1 Δ in %
Current Ratio 2.88 2.61 -9.42
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA -2.55 -1.86 26.81
Naive Interpretation Member
06 - Financial Health · Bad
End of WST's Analysis
CIK: 105770 CUSIP: 955306105 ISIN: US9553061055 LEI: - UEI: -
Secondary Listings
WST has no secondary listings inside our databases.